-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In 2021, domestic biopharmaceuticals will set off a wave of financing
.
According to incomplete statistics, in the first half of the year alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount exceeding 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan
.
The time has come to 2022, and this wave of financing is still continuing.
Recently, many innovative pharmaceutical companies have announced the completion of financing
.
For example, on January 24, Nanjing Yuxi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Yuxi Medicine") announced that it has recently completed a pre-A round of tens of millions of RMB financing.
This round of financing was led by Materia Medica and Jiuyou.
Capital, Chang Development, Aibo Qingshi and Mingfeng Capital joined the investment, and the original shareholders Yingdi Capital and Tibet Gaoge continued to bless
.
This round of financing will be mainly used for product clinical trials, pipeline research and development, innovative technology platform construction and team replenishment
.
It is understood that Yuxi Medicine is a company focusing on the research and development of new and improved drugs in the skin field, and is committed to meeting the unmet needs of all aspects of the skin health industry chain
.
Focusing on the "innovative long-acting transdermal technology platform" with its own intellectual property rights, the company has built a product pipeline that includes multiple new drugs under development.
Among them, the fast-moving product, IDT-001, will undergo clinical trials in 2022
.
Coincidentally, Yuguo Bio has also announced the completion of a C round of financing of 300 million yuan, which was exclusively led by Shanghai Biomedical Fund and followed by the old shareholder LYFE Zhouling Capital
.
According to the data, Yuguo Bio is a microbial sequencing and genome big data analysis service provider.
At present, the company has successfully developed PACE (PAthogen Capture Engine), a cloud-based pathogenic microorganism data analysis system with international level
.
According to the announcement, the funds raised in this round will continue to be invested in the research and development of new products and the in-hospital localization deployment of pathogenic NGS
.
It is worth mentioning that Yuguo Bio has completed multiple rounds of equity financing.
Since the last round of financing, the business side has grown very rapidly and has become one of the leading companies in the industry.
.
In addition to the above-mentioned companies, Wuhan Ruijian Pharmaceutical Technology Co.
, Ltd.
(referred to as "Ruijian Medicine"), which is committed to the development of chemically induced adult cell drugs, also recently announced the completion of nearly 100 million yuan in Series A + financing
.
It is reported that this round of financing will be mainly used to promote the development of the NouvNeu001 clinical phase 1 study of Ruijian Pharmaceutical's pipeline for Parkinson's disease, and at the same time support the company's follow-up pipeline NS001 for Sino-US new drug clinical research
.
According to the data, Ruijian Pharmaceutical is a high-tech pharmaceutical company focusing on the regeneration of functional cells induced by high-efficiency chemical small molecules
.
At present, focusing on the research and transformation of cell fate regulation mechanism, Ruijian Medicine has built a cell drug research and development technology platform based on chemical induction of small molecules, and has carried out a multi-faceted and systematic patent layout, focusing on specific degenerative and traumatic diseases.
Develop off-the-shelf cell drugs with independent intellectual property rights for diseases, tumors and metabolic diseases
.
From the above overall point of view, the industry believes that behind the continuous entry of capital, it is actually the performance of the continuous rise of China's biopharmaceutical industry
.
In the future, as more and more strategic investors pay more attention to pharmaceutical biology and increase investment, it is expected to inject more innovation impetus into the pharmaceutical and biological market, thereby better promoting the emergence and high-quality development of innovation achievements in the pharmaceutical and biological industry.
.
.
According to incomplete statistics, in the first half of the year alone, the number of IPO pharmaceutical companies on the Science and Technology Innovation Board has reached 23, with a total financing amount exceeding 18 billion yuan
.
Among them, many pharmaceutical companies have raised more than 1 billion yuan
.
The time has come to 2022, and this wave of financing is still continuing.
Recently, many innovative pharmaceutical companies have announced the completion of financing
.
For example, on January 24, Nanjing Yuxi Pharmaceutical Technology Co.
, Ltd.
(hereinafter referred to as "Yuxi Medicine") announced that it has recently completed a pre-A round of tens of millions of RMB financing.
This round of financing was led by Materia Medica and Jiuyou.
Capital, Chang Development, Aibo Qingshi and Mingfeng Capital joined the investment, and the original shareholders Yingdi Capital and Tibet Gaoge continued to bless
.
This round of financing will be mainly used for product clinical trials, pipeline research and development, innovative technology platform construction and team replenishment
.
It is understood that Yuxi Medicine is a company focusing on the research and development of new and improved drugs in the skin field, and is committed to meeting the unmet needs of all aspects of the skin health industry chain
.
Focusing on the "innovative long-acting transdermal technology platform" with its own intellectual property rights, the company has built a product pipeline that includes multiple new drugs under development.
Among them, the fast-moving product, IDT-001, will undergo clinical trials in 2022
.
Coincidentally, Yuguo Bio has also announced the completion of a C round of financing of 300 million yuan, which was exclusively led by Shanghai Biomedical Fund and followed by the old shareholder LYFE Zhouling Capital
.
According to the data, Yuguo Bio is a microbial sequencing and genome big data analysis service provider.
At present, the company has successfully developed PACE (PAthogen Capture Engine), a cloud-based pathogenic microorganism data analysis system with international level
.
According to the announcement, the funds raised in this round will continue to be invested in the research and development of new products and the in-hospital localization deployment of pathogenic NGS
.
It is worth mentioning that Yuguo Bio has completed multiple rounds of equity financing.
Since the last round of financing, the business side has grown very rapidly and has become one of the leading companies in the industry.
.
In addition to the above-mentioned companies, Wuhan Ruijian Pharmaceutical Technology Co.
, Ltd.
(referred to as "Ruijian Medicine"), which is committed to the development of chemically induced adult cell drugs, also recently announced the completion of nearly 100 million yuan in Series A + financing
.
It is reported that this round of financing will be mainly used to promote the development of the NouvNeu001 clinical phase 1 study of Ruijian Pharmaceutical's pipeline for Parkinson's disease, and at the same time support the company's follow-up pipeline NS001 for Sino-US new drug clinical research
.
According to the data, Ruijian Pharmaceutical is a high-tech pharmaceutical company focusing on the regeneration of functional cells induced by high-efficiency chemical small molecules
.
At present, focusing on the research and transformation of cell fate regulation mechanism, Ruijian Medicine has built a cell drug research and development technology platform based on chemical induction of small molecules, and has carried out a multi-faceted and systematic patent layout, focusing on specific degenerative and traumatic diseases.
Develop off-the-shelf cell drugs with independent intellectual property rights for diseases, tumors and metabolic diseases
.
From the above overall point of view, the industry believes that behind the continuous entry of capital, it is actually the performance of the continuous rise of China's biopharmaceutical industry
.
In the future, as more and more strategic investors pay more attention to pharmaceutical biology and increase investment, it is expected to inject more innovation impetus into the pharmaceutical and biological market, thereby better promoting the emergence and high-quality development of innovation achievements in the pharmaceutical and biological industry.
.
